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Brief Technique Reportsoffer advantages such as avoidance of a hostile mediastinum
with previous coronary bypass grafts and adhesed chambers.
In the case of endocannulae and endo-occlusion, they offer
the ability to perform the procedure with a single incision
on the heart. There are disadvantages, such as the need to dis-
sect out the aorta if a crossclamp is used and retrograde arte-
rial flow if the femoral system is used. Additionally, older
data with femoral access and endoballoon occlusion had
shown high dissection rates,2 although this has not been
the case in more modern series of port access surgery.3
In our case, because the patient had a previous stroke and
multiple previous procedures in a moderately calcified sys-
tem, we preferred antegrade flow and chose an axillary can-
nulation strategy. Additionally, inasmuch as we wished to
minimize dissection of the aorta from a right chest
approach, we chose to place the endoballoon through the
axillary chimney. This strategy yielded excellent flows of
up to 5 L/min when using vacuum-assisted drainage and
a 25F multilumen femoral venous cannula. Although we
could have chosen a cold fibrillatory strategy, the aortic in-
sufficiency and the need to remove a heavily entrenched
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464 The Journal of Thoracic and Cardiovascular Surgantegrade cardioplegia through the aortic root and intermit-
tent retrograde cardioplegia through the coronary sinus,
along with moderate (28C) hypothermia, provided excel-
lent protection during the right thoracotomy. Separation
from bypass was uneventful. Postoperatively, he continues
to do well and is pleased with the cosmetic aspect of the
scar as well (Figure 1, B).
To our knowledge, this is one of the few reports of axil-
lary cannulation with an endoballoon placed through the ax-
illary cannula. In our hands, it was a reasonable strategy for
complex reoperative mitral surgery and may be an interest-
ing method for providing antegrade flow and a single suture
line on the heart when performing mitral valve surgery.References
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Dimitrios T. Kremastinos, MD, FESC,b Thessaloniki and Athens, GreeceDespite expert opinion that mechanical circulatory sup-
port (MCS) should be considered before the sequelae of se-
vere right ventricular (RV) failure, biventricular support is
applied in a significant percentage of long-term MCS
recipients and is associated with increased mortality
compared with mortality after isolated left ventricular
(LV) support.1
Total artificial heart and biventricular MCS application
is closely related to transplant eligibility.2 Transplant-
ineligible patients with refractory biventricular failure have
no treatment options other than end-of-life care.Implantation of newer-generation, long-term, continuous-
flow left ventricular assist devices (LVADs) has contributed
to improved results of MCS.3 Long-term, continuous-flow,
right ventricular assist devices (RVADs) do not exist, and
long-term biventricular support with the new pumps has
not been reported.CLINICAL SUMMARY
We report the first cases of elective, single-stage, LV
and RV support with 2 second-generation axial flow pumps.
We applied total ventricular assist (tVA) as long-term treat-
ment to 2 male patients with ischemic and idiopathic
end-stage biventricular failure in Interagency Registry for
Mechanically Assisted Circulatory Support profiles 2 and
3. The patients were not suitable for transplantation because
of advanced age and diabetes mellitus with end-organ
damage; the second patient also had fixed pulmonary hyper-
tension, increased pulmonary vascular resistance, and
transpulmonary gradient (Table 1). Institutional ethics com-
mittee approval and informed consent were obtained in both
cases.ery c August 2011
TABLE 1. Preimplantation patient characteristics and postimplantation outcomes
Patient 1 Patient 2
Sex/age (y)/BSA (m2) Male/65/1.81 Male/68/1.92
Pathology Ischemic cardiomyopathy Idiopathic dilated cardiomyopathy
Symptoms and signs Dyspnea, fatigue, and exercise intolerance at greater than 1 year; recent (3–6 mo) establishment of jugular
vein distention, pleural effusions, hepatomegaly, ascites, and leg edema; hepatic impairment
(patient 2: chronic renal failure)
INTERMACS profile 2 3
BNP/proBNP (pg/mL) 4820/>3000 843/9114
Previous procedures CABG 3 2, mitral valve repair Implantation of cardioverter defibrillator
Insulin-dependent
diabetes mellitus
Duration: 20 y, diabetic retinopathy,
diabetic neuropathy;
history of feet ulcers
Duration: 4 y, diabetic retinopathy, diabetic nephropathy
Preoperative right-sided heart catheterization data
CO (L/min)/CI (L $ min1 $ m2) 2.9/1.6 2.5/1.3
RAP (mm Hg) 28 19
PAP S/D (mm Hg [mean]) 51/29 (40) 57/33 (43)
PWP (mm Hg) 32 27
PVR (Wood units) 2.75 6.4
RVSWI (g/m) 3.4 4.5
Laboratory data* Before implantation After implantation Before implantation After implantation
Total bilirubin (mg/dL) 2.72 (2.5–4.39) 2.03 (2.03–5.53) 1.09 (1.091.96) 1.11 (1.11–2.23)
Urea (mg/dL) 123 (99–140) 47 (46–102) 104 (85–141) 60 (54–117)
Creatinine (mg/dL) 1.14 (0.97–1.26) 0.88 (0.56–1.1) 1.97 (1.97–2.75) 2.11 (1.26–2.85)
Echocardiographic data Before implantation After implantation Before implantation After implantation
LVDD (cm)/LVSD (cm) 6.1/5.7 5.9/5 5.9/5.3 5.6/5
LVDV (mL)/LVSV (mL) 185/159 172/120 171/134 151/117
LVEF (%)/LVFS (%) 14/6.5 30.1/14.4 22/10.2 21/9.7
RVDD/RVDD SAX (cm) 4.4/5.1 3.5/3.6 4.2/5.3 2.3/3.7
TV annulus (cm) 4.5 3.5 5.7 4.2
TR (grade1–4) 3 1 3 1
MR (grade1–4) 0 0 2 —
TV Sm (TDI; cm/s) 4.7 — 6.5 0
Ventilation/ICU/hospital stay (d) 3/13/47 3/6/20
BP, RAP during ICU stay 79.9/15.2 87.3/10.2
Indices of appropriate tVA: Mean systemic arterial pressure>70 mm Hg; desirable of a degree of pulsatility, at least during intermittent low speed; good
urine output; and normal pH and lactate concentration. Decreased CVP, good arterial oxygenation, and no pulmonary congestion (normal auscultation,
normal lung translucency). Normalizing hepatic and renal function. Adequate ventricular filling and unloading: RVDD35mm, LVDD<60mm,midline
position of intraventricular and intra-atrial septum, and decreased TR and MR.
BSA, Body surface area; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; BNP, B-type natriuretic peptide; CABG, coronary artery bypass
grafting; CO, cardiac output; CI, cardiac index; RAP, right atrial pressure; PAP, pulmonary artery pressure; S/D, systolic/diastolic; PWP, pulmonary wedge pressure; PVR, pul-
monary vascular resistance; RVSWI, right ventricular stroke work index; LVDD, left ventricular diastolic diameter; LVSD, left ventricular systolic diameter; LVDV, left ventricular
diastolic volume; LVSV, left ventricular systolic volume; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; RVDD, right ventricular diastolic
diameter; RVDD SAX, right ventricular diastolic diameter short-axis apical view; TV, tricuspid valve; TR, tricuspid regurgitation; MR, mitral regurgitation; TV Sm (TDI), peak
lateral TVannulus velocity (tissue Doppler imaging); ICU, intensive care unit; BP, blood pressure (systemic); BP, RAP during ICU stay, mean blood pressure (systemic) and mean
RAP during postimplantation intensive care unit stay; tVA, total ventricular assist. *Laboratory data before implantation: Immediate preimplantation value (range during pre-
implantation hospitalization). Laboratory data after implantation: at hospital discharge (range during postimplantation hospitalization).
Brief Technique ReportsTwo Jarvik 2000 pumps were implanted through a left
thoracotomy (the usual approach for the Jarvik LVAD im-
plantation). One large skin flap was created, and 2 pedestals
were fixed to the left postauricular area at places with suffi-
cient skull thickness (>8.8 mm on computed tomographic
analysis).
The devices were implanted on a beating heart without
extracorporeal circulation to minimize end-organ insult.
The LVAD was implanted first (pump insertion into the
left ventricle and outflow graft anastomosis to theThe Journal of Thoracic and Cadescending thoracic aorta). With minimal LVAD support
(8000 rpm), the RVAD was then implanted (pump insertion
into the right ventricle and outflow graft anastomosis to the
left pulmonary artery) and started at a minimal speed (8000
rpm, Figure 1).
Intraoperatively, under direct vision and hemodynamic and
echocardiographic monitoring, the LVAD speed was
gradually increased to 10,000 rpm and the RVAD speed to
9000 rpm. These settings provided good hemodynamic
response and remained unchanged for the whole period ofrdiovascular Surgery c Volume 142, Number 2 465
FIGURE 1. Total ventricular assist with 2 Jarvik 2000 continuous axial flow intraventricular pumps first applied on March 25, 2009. Elective single-stage,
off-pump, beating-heart (without ventricular fibrillation) implantation of 2 pumps through a left thoracotomy, which provided good access to the left ven-
tricular apex and to the diaphragmatic surface of the right ventricle close to the acute margin and the RVapex without major cardiac distortion, facilitating
implantation without hemodynamic compromise is shown. Furthermore, it was advantageous in the first patient who had undergone a median sternotomy
and had patent, skeletonized bilateral internal thoracic artery grafts beneath the sternum. After feasibility of implantation and good exposure was shown in
the first patient, the same implantation method was adapted in the second patient. A, Head–neck and chest radiographs of the first patient. One tunnel was
created for both power cables, and 2 pedestals were screwed to the left postauricular and supra-auricular area of the skull. LP, Left pedestal; RP, right ped-
estal; RVAD pump, right ventricular assist device pump (inside the right ventricle); LVAD pump, left ventricular assist device pump (inside the left ventricle).
B, Schematic representation of implantation of 2 Jarvik 2000 pumps for total ventricular assist. Left ventricular assist device pump inflow is ‘‘facing’’ the
mitral valve. Right ventricular assist device pump inflow is ‘‘facing’’ the pulmonary valve. The left ventricular assist device outflow graft was anastomosed
to the descending thoracic aorta. The right ventricular assist device outflow graft was anastomosed to the left pulmonary artery. C, Photograph of the first
patient on the 42nd day of support. LP, Left pedestal; RP, right pedestal. The left ventricular assist device pedestal was fixed at a high point of the left
postauricular area, and the right ventricular assist device pedestal was fixed superiorly and posteriorly to it. The pedestal fixation areas need not be strictly
postauricular. At both places, the skull had sufficient thickness of greater than 8.8 mm, as measured on preoperative computed tomographic analysis.
Fixation to the skull and increased area vascularity ensured excellent wound healing with minimal care.
Brief Technique Reportssupport. The RVAD speed was always kept at less than the
LVAD speed to minimize the chances of pulmonary edema.
Two standard intermittent low-speed controllers were used
for each patient (with asynchronous intermittent low-speed
periods).
The patients were managed without measurement of
pump flows. Pulmonary artery catheter placement was
avoided because of the RV pump. Monitoring of standard
hemodynamic, echocardiographic, laboratory, and clinical
indices was adequate for postoperative management.
Early postoperatively, milrinone infusion and inhaled ilo-
prost were administered. The circulation was successfully
supported, end-organ function was maintained or improved,
and the patients were extubated early, rehabilitated, dis-
charged home, and resumed progressively increasing phys-
ical activity without any episodes of low output syndrome,466 The Journal of Thoracic and Cardiovascular Surgpulmonary congestion, edema, embolism, hemoptysis, or
organ failure (Table 1).
Anticoagulation included heparin infusion after the first
12 postoperative hours, conversion to oral acenocoumarol,
and antiplatelet treatment individualized according to clin-
ical and laboratory parameters. Both patients were dis-
charged on a low dose of acetylsalicylic acid (100 mg)
and acenocoumarol, aiming at an international normalized
ratio of 2.5 to 3.5 (baseline). Dipyridamole (75 mg twice
daily) was added to the baseline anticoagulation regimen
of the second patient after a minor ischemic stroke.
The first patient was supported for 6.7 months and died of
septic complications related to a diabetic foot. The second pa-
tient was supported for 88 days and died after cerebral bleed-
ing while receiving dual antiplatelet treatment and having an
international normalized ratio at a subtherapeutic range (1.7).ery c August 2011
Brief Technique ReportsSerial echocardiographic analysis revealed systolic
opening of the pulmonary valve at every beat (partial
opening during nominal speed and wider opening during in-
termittent low speed) and systolic opening of the aortic
valve mainly during intermittent low speed.DISCUSSION
It appears that preserved integrity of the cardiovascular
system and partial biventricular support acting synergisti-
cally with the autoregulated residual biventricular function
compensated for any flow imbalances between the 2 devices.
Biventricular support with the Jarvik 2000 had been pre-
viously applied as a 2-stage procedure (RVAD implantation
after presentation of RV failure) with a different surgical
technique (median sternotomy, RVAD pump implantation
inside the right atrium, and outflow graft anastomosis to
the main pulmonary artery) and maintained for 12 days.
Good hemodynamic response was reported.4 We preferred
elective application of tVA because of severe preoperative
RV failure5 and intraventricular RVAD implantation insteadThe Journal of Thoracic and Caof bypassing the RV to minimize the chances of suctioning
and thromboembolism.
If further investigation validates that tVA is reproducible,
advanced device technology will be added to the armamen-
tarium of durable cardiac assist.
We thank Dr Emmanuil Psaltis and the architect Stylianos
Psaltis for designing Figure 1, B.
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